American Thoracic Society - Sanofi Investor Call
sanofi
-
COPD Following the science with decisive actions
Direct-to-Phase 3 program
Investment de-risked with interim analysis
IL4/IL13 plays a
mechanistic role in
pathologic processes
in Type 2 COPD
DUPIXENT
(dupilumab)
Patient population
optimized based
on IL-5 learnings
Prior data support
Type 2 COPD guided
by eosinophils
Targeting
differential
efficacy for FiC/BIC
•
High unmet need with no approved
biologics
3rd leading cause of death WW, COPD
carries a severe burden and leads to
progressive loss of lung function
• Typically treated with inhaled
bronchodilators and steroids -"one size fits
all" therapies with small treatment effects
Potential to be first- and best-in-class
Opportunity to reinforce respiratory
market leadership
Dupixent® is under investigation in COPD and not yet approved by any regulatory agency to treat this indication.
12 ATS Investor CallView entire presentation